CHMP recommends expanded use for Alexion’s PNH therapy Ultomiris

AstraZeneca’s (AZ) Ultomiris has received a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to expand its use to include children and adults with paroxysmal nocturnal haemoglobinuria (PNH).